Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.
Actively Recruiting
Researchers are comparing the effectiveness and safety of sonrotoclax combined with either obinutuzumab or rituximab against venetoclax combined with rituximab in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase 3 study aims to assess progression-free survival and other important outcomes among these treatment combinations to find better options for patients. Participants will be randomly assigned to one of four treatment groups sonrotoclax plus obinutuzumab, sonrotoclax plus rituximab, sonrotoclax plus obinutuzumab guided by minimal residual disease evaluation, or venetoclax plus rituximab. Sonrotoclax and venetoclax are given orally, while obinutuzumab and rituximab are given intravenously. The study includes detailed treatment schedules and monitoring of minimal residual disease in one group. During the study, participants will have regular evaluations including assessments by blinded independent review committees of progression-free survival, response rates, and overall survival. Quality of life and symptom burden will also be measured using specific questionnaires. Safety will be monitored from the first dose through follow-up periods lasting up to several years. The total study duration extends to approximately six years, with ongoing assessments to understand treatment effects and safety.
Actively Recruiting
The trial investigates treatment options for adults aged 18 to 70 with newly diagnosed higher-risk myelodysplastic syndromes HR-MDS, focusing on the feasibility of allogeneic stem cell transplantation HSCT. It compares upfront HSCT with pre-treatment using azacitidine or conventional chemotherapy based on the patients bone marrow blast counts. This phase III, open-label, randomized multicenter study aims to determine whether pre-transplant treatments affect the ability to proceed with HSCT. Participants are assigned to groups depending on their bone marrow blast levels. Those with 10% or more blasts receive either conventional chemotherapy following a 37 protocol or azacitidine given subcutaneously at 75 mgm2 daily for 7 days every 28 days for at least 4 cycles before HSCT if a suitable donor is available. Patients with less than 10% blasts may receive upfront HSCT or azacitidine prior to HSCT under similar dosing schedules. The study evaluates these different sequences of therapy to assess HSCT feasibility. During the study, participants undergo regular assessments over four years to monitor whether they proceed to HSCT. Researchers track treatment outcomes, safety, and overall feasibility by measuring the proportion of randomized patients who receive the transplantation. The trial includes follow-up for at least four years to collect data on these outcomes and ensure participant safety and treatment adherence throughout the process.
Actively Recruiting
Researchers are evaluating the effect of adding gemtuzumab ozogamicin to standard chemotherapy for adults aged 18 to 60 with newly diagnosed favorable or intermediate-risk acute myeloid leukemia AML. This phase 3 study aims to reduce minimal residual disease MRD levels before transplantation and assess whether MRD-driven post-remission therapy can improve anti-leukemic outcomes. The study excludes patients with certain genetic markers or prior treatments to focus on a specific AML subgroup. Participants receive induction treatment with gemtuzumab, daunorubicin, and cytosine arabinoside, followed by consolidation therapy with adjusted doses of these drugs. After consolidation, patients undergo either autologous or allogeneic stem cell transplantation based on their MRD level. This MRD-guided approach helps tailor the intensity of post-remission therapy. Throughout the study, participants undergo MRD assessments to measure treatment activity, with the primary outcome being MRD negativity two months after starting therapy. Researchers also monitor kidney and liver function, heart health, and overall compliance with study procedures. The study involves regular clinical observations and assessments to evaluate the effectiveness of the combined treatment and its impact on MRD levels over time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tucatinib combined with trastuzumab and capecitabine in adult women with HER2-positive metastatic breast cancer in a real-world setting. This observational study includes patients who have previously received multiple HER2-targeted treatments and aims to understand how this combination therapy works outside of clinical trials. HER2 is a protein that promotes cancer cell growth and is overexpressed in about 20% of breast cancers. Tucatinib is an oral drug that selectively inhibits the HER2 protein, and this study follows approved treatment guidelines and doses. Patients will receive tucatinib, trastuzumab, and capecitabine as prescribed by their doctors according to local clinical practice without any additional treatment procedures mandated by the study. The study is non-interventional and multicenter, enrolling about 300 women who are candidates for tucatinib therapy, including those with prior treatments such as trastuzumab, pertuzumab, T-DM1, and T-DXd. Patients will be observed during their treatment period and followed for 18 months after finishing tucatinib therapy to monitor outcomes and safety. During the study, researchers will collect baseline data, safety information, and performance status using the Eastern Cooperative Oncology Group ECOG score. They will assess response to treatment and survival based on clinicians evaluations and local practice. Follow-up will include monitoring for symptoms, treatment response, and survival status for 18 months post-treatment. The study also records any treatments patients receive before or after tucatinib therapy to better understand its real-world effectiveness and safety.
Actively Recruiting
Researchers are evaluating the impact of a healthy lifestyle implemented Survivorship Care Plan LS-SCP on the quality of life in long-term lymphoma survivors who have been in remission for at least 3 years and up to 10 years. This is a prospective, randomized, open-label, multicenter study involving two groups to compare the effects of the lifestyle plan versus standard follow-up care. Participants in the experimental group will follow a Survivorship Care Plan that includes nutritional guidance and physical activity recommendations for 6 months. Compliance with this plan will be monitored through automatic bi-monthly phone calls. The control group will receive no specific intervention and will continue with usual clinical follow-up, completing questionnaires at 6 and 12 months after randomization. During the study, all participants will complete validated questionnaires assessing quality of life, fatigue, anxiety, depression, and other health aspects at baseline, 6 months, and 12 months. Clinical assessments and evaluations of metabolic and cardiovascular outcomes, cognitive function, and adherence to healthy lifestyles will also be conducted. The main outcome measured is the global quality of life over a period of up to 30 months from the study start.
Actively Recruiting
Researchers are investigating advanced follicular lymphoma FL by studying the role of EZH2 gene changes in patients treated with immunochemotherapy. This study is linked to the FILFOLL12 trial, which enrolled 807 patients and compared first-line treatments using chemoimmunotherapy combinations like R-CHOP or bendamustine-rituximab BR. The goal is to find biomarkers that can guide doctors in selecting the best chemotherapy approach for each patient. The study involves analyzing biological samples such as bone marrow, peripheral blood, and diagnostic tumor tissue. Tests include detecting EZH2 mutations using droplet digital PCR and examining gene expression patterns with RNA sequencing. Researchers will also explore other markers related to disease diversity, minimal residual disease, genetic factors, and microbiome profiles. These tests build on samples collected during the original FILFOLL12 trial. Participants have already been enrolled in the FILFOLL12 trial and provided biological samples. Researchers will measure outcomes like progression-free survival up to 43 months after treatment start, response rates within several months, and the relationship between gene mutations and expression patterns. The study is observational and focuses on laboratory analyses without additional treatments. It aims to provide practical biomarkers for clinical use and establish a network of laboratories for timely testing.
Actively Recruiting
This research aims to evaluate the effects of adding Vitamin D supplementation to standard immunochemotherapy in elderly patients diagnosed with Diffuse Large B-Cell Lymphoma or Follicular grade IIIb lymphoma. This open-label, randomized phase III trial compares two treatment approaches to understand whether Vitamin D affects outcomes in patients aged 65 and older undergoing immunochemotherapy. Participants are randomly assigned to one of two groups. Both groups receive a prephase of oral prednisone followed by six cycles of immunochemotherapy with R-CHOP or R-miniCHOP every 21 days. The experimental group also receives Vitamin D supplementation starting before treatment and continuing through immunochemotherapy according to a set schedule, including loading doses based on baseline Vitamin D levels and weekly maintenance. Patients may continue Vitamin D supplementation after treatment for up to two years. During the study, participants undergo baseline assessments and are monitored regularly through the treatment cycles. Researchers track progression-free survival over 54 months as the primary outcome, along with overall survival, response rates, Vitamin D levels, physical functioning, and fatigue. Safety and treatment adherence are also monitored, with follow-up visits extending up to several years to evaluate long-term outcomes.
Actively Recruiting
Researchers are investigating a new treatment approach for adults with newly diagnosed acute myeloid leukemia AML who have specific genetic mutations NPM1 or KMT2A and are not eligible for intensive chemotherapy. Although current treatment combining azacitidine and venetoclax has improved outcomes, it is not curative and relapses occur. This Phase 3 study aims to determine if adding the investigational drug revumenib, which blocks a molecule called menin involved in leukemia cell production, can improve patient prognosis. Participants will be randomly assigned to receive either revumenib or a placebo, both in combination with azacitidine and venetoclax. Treatment cycles last 28 days and continue until the disease progresses, unacceptable side effects develop, death occurs, or other protocol criteria require stopping treatment. After the last patient joins the study, there will be a 4-year follow-up period to monitor survival and conduct additional visits. During the study, participants will undergo regular assessments to evaluate overall survival, remission rates, event-free survival, quality of life, and molecular responses using bone marrow and blood tests. Safety and treatment effects will be closely monitored throughout the treatment and follow-up periods. Participants must be adults with confirmed mutations and meet specific health criteria to join this trial.
Actively Recruiting
Researchers are conducting an international, multicenter, observational, and retrospective study focusing on patients diagnosed with plasmablastic lymphoma PBL. The study aims to gather detailed information on the clinical and pathological features, treatment approaches, outcomes, and prognostic factors such as clinical data, biomarkers, and radio-metabolic indicators in individuals affected by PBL. A centralized review of pathological samples is planned to assess diagnostic accuracy and to recommend an immunohistochemical panel for PBL diagnosis. Participants are patients diagnosed with PBL between January 1, 2000, and December 31, 2022, confirmed by histological analysis. The study will collect data from real-life diagnosis, staging, treatment regimens, and outcomes. Exploratory analyses will also be conducted to better understand PBL characteristics. This is an observational study without active treatment interventions. Participants medical records and histopathological materials will be reviewed and analyzed. The research team will evaluate outcomes such as overall survival at 36 months, disease staging, treatment response rates, progression-free survival, and other clinical factors. Data on chemotherapy regimens, involvement of specific organs, and frequencies of HIV and EBV at relapse will also be assessed. The study will continue until February 2028, with ongoing data collection and analysis.